Compare Okta, Inc. (OKTA) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Oruka Therapeutics Inc. Common Stock — how do they compare? Okta, Inc. trades at $208.5 (market cap $39.60B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Okta, Inc. is far larger — about 7.6× Oruka Therapeutics Inc. Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| OKTA | ORKA | |
|---|---|---|
Market Cap | $39.60B | $5.18B |
Volume | 2,315,203 | 490,798 |
Sector | Technology | Health |
52-Week High | $232.13 | $113.08 |
52-Week Low | $62.93 | $26.19 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $37.36B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $211.92, down 6.68% today, but maintains strong analyst support with 74% buy ratings and a consensus price target of $201.76. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $0.93. Revenue growth remains robust, climbing from $1.3B in 2022 to $2.6B in 2025, while achieving positive net income of $28M after years of losses. Technical indicators show a bullish trend with key support at $215.
OKTA presents a compelling growth story with improving profitability and strong positioning in identity management. The stock faces valuation concerns with a P/E of 136, but AI security initiatives and consistent earnings beats provide catalysts. Key risks include high valuation multiples and competitive pressures in cybersecurity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
